{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T21:24:21Z","timestamp":1793309061156,"version":"4.5.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To evaluate, in eyes with radiation maculopathy, the effect of 2-month-interval anti\u2013vascular endothelial growth factor therapy on best-corrected visual acuity and foveal avascular zone (FAZ) enlargement using optical coherence tomography angiography.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Consecutive treatment-naive patients with radiation maculopathy after proton beam irradiation for choroidal melanoma were retrospectively included. Clinical and optical coherence tomography angiography data at baseline and the 6-month visit were recorded. Two independent observers measured FAZ area manually on 3 \u00d7 3-mm optical coherence tomography angiography images of the superficial capillary plexus and deep capillary plexus. Patients were encouraged to follow strictly a 2-month-interval intravitreal anti\u2013vascular endothelial growth factor treatment by either bevacizumab or ranibizumab. Findings were analyzed based on the adherence to the treatment scheme.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>According to the adherence to the bimonthly anti\u2013vascular endothelial growth factor treatment protocol, patients were categorized into 3 groups: treatment protocol (n = 19, strict adherence), variable intervals (n = 11, intervals other than 2 months), and no treatment (n = 11). The estimated radiation dose to the foveola in each group was 49 \u00b1 16, 46 \u00b1 17, and 46 \u00b1 18 cobalt gray equivalent, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.85). For the entire cohort, best-corrected visual acuity loss (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.02) and FAZ enlargement (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.0001) were observed over 6 months. Best-corrected visual acuity loss was significantly less pronounced in the treatment-protocol group than in the variable-interval and no-treatment groups (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.007 and <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.004). The FAZ enlargement was lower in the treatment-protocol group compared with the variable-interval group for both superficial capillary plexus (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.029) and deep capillary plexus (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.03), and to the no-treatment group for the deep capillary plexus only (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.016).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Decrease in best-corrected visual acuity and FAZ enlargement on optical coherence tomography angiography occurred over 6 months in eyes with radiation maculopathy and were significantly reduced under 2-month-interval anti-vascular endothelial growth factor therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000002200","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T01:37:20Z","timestamp":1525916240000},"page":"1519-1526","source":"Crossref","is-referenced-by-count":23,"title":["INTRAVITREAL ANTI\u2013VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT AT 2-MONTH INTERVALS REDUCES FOVEAL AVASCULAR ZONE ENLARGEMENT AND VISION LOSS IN RADIATION MACULOPATHY"],"prefix":"10.1097","volume":"39","author":[{"given":"Alejandra","family":"Daruich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Matet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Schalenbourg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonidas","family":"Zografos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230816","first-page":"241","article-title":"Uveal melanoma: relatively rare but deadly cancer","volume":"31","author":"Kaliki","year":"2017","journal-title":"Eye Lond Engl"},{"key":"R2-20230816","first-page":"T2","article-title":"Ranibizumab for the prevention of radiation complications in patients treated with proton beam irradiation for choroidal melanoma","volume":"114","author":"Kim","year":"2016","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R3-20230816","doi-asserted-by":"crossref","first-page":"60","DOI":"10.5301\/ejo.5000670","article-title":"Intravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study","volume":"26","author":"Finger","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"R4-20230816","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ophtha.2013.08.039","article-title":"Intravitreal bevacizumab at 4-month intervals for prevention of macular edema after plaque radiotherapy of uveal melanoma","volume":"121","author":"Shah","year":"2014","journal-title":"Ophthalmology"},{"key":"R5-20230816","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ajo.2014.07.002","article-title":"Prophylactic use of bevacizumab to avoid anterior segment neovascularization following proton therapy for uveal melanoma","volume":"158","author":"Mantel","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R6-20230816","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/jamaophthalmol.2015.0668","article-title":"A promising future for optical coherence tomography angiography","volume":"133","author":"Nagiel","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R7-20230816","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1097\/IAE.0000000000001021","article-title":"Optical coherence tomography angiography of the macula after plaque radiotherapy of choroidal melanoma: comparison of irradiated versus nonirradiated eyes in 65 patients","volume":"36","author":"Shields","year":"2016","journal-title":"Retina"},{"key":"R8-20230816","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ajo.2016.04.024","article-title":"Antiangiogenic or corticosteroid treatment in patients with radiation maculopathy after proton beam therapy for uveal melanoma","volume":"168","author":"Seibel","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R9-20230816","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1167\/iovs.16-20579","article-title":"Optical coherence tomography angiography analysis of the foveal avascular zone and macular vessel density after anti-VEGF therapy in eyes with diabetic macular edema and retinal vein occlusion","volume":"58","author":"Ghasemi Falavarjani","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R10-20230816","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/bjophthalmol-2015-307330","article-title":"Reproducibility and repeatability of foveal avascular zone measurements in healthy subjects by optical coherence tomography angiography","volume":"100","author":"Carpineto","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R11-20230816","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ajo.2015.09.026","article-title":"Measurement of foveal avascular zone dimensions and its reliability in healthy eyes using optical coherence tomography angiography","volume":"161","author":"Shahlaee","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R12-20230816","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1097\/IAE.0000000000001426","article-title":"Reproducibility and reliability of optical coherence tomography angiography for foveal avascular zone evaluation and measurement in different settings","volume":"37","author":"La Spina","year":"2017","journal-title":"Retina"},{"key":"R13-20230816","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ophtha.2014.03.021","article-title":"Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema","volume":"121","author":"Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"key":"R14-20230816","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00055735-199406000-00011","article-title":"Ionizing radiation and the retina","volume":"5","author":"Archer","year":"1994","journal-title":"Curr Opin Ophthalmol"},{"key":"R15-20230816","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/ICU.0b013e3283386687","article-title":"Classification and treatment of radiation maculopathy","volume":"21","author":"Horgan","year":"2010","journal-title":"Curr Opin Ophthalmol"},{"key":"R16-20230816","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1074\/jbc.271.2.603","article-title":"Vascular endothelial growth factor, a potent and selective angiogenic agent","volume":"271","author":"Thomas","year":"1996","journal-title":"J Biol Chem"},{"key":"R17-20230816","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/S0959-8049(96)00387-5","article-title":"Vascular endothelial growth factor","volume":"32A","author":"Ferrara","year":"1996","journal-title":"Eur J Cancer"},{"key":"R18-20230816","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.exer.2011.09.010","article-title":"Comparison of choroidal and retinal endothelial cells: characteristics and response to VEGF isoforms and anti-VEGF treatments","volume":"93","author":"Stewart","year":"2011","journal-title":"Exp Eye Res"},{"key":"R19-20230816","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/bjo.2006.095190","article-title":"Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells","volume":"90","author":"Spitzer","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R20-20230816","first-page":"321","article-title":"Bevacizumab inhibits proliferation of choroidal endothelial cells by regulation of the cell cycle","volume":"7","author":"Rusovici","year":"2013","journal-title":"Clin Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006982-201908000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:29:40Z","timestamp":1692232180000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201908000-00010"}},"subtitle":["A Pilot Study"],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000002200","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}